Costimulatory trispecific antibodies, combining binding to a tumor antigen, CD3, and additional receptors (4-1BB, OX40, or CD28), enhance T-cell activation and proliferation, increase metabolic activity, and decrease exhaustion markers. This evidence concerns the gene TNFRSF9 and neoplasm.